A groundbreaking study shows findings that show a treatment can shrink tumors and improve survival outcomes for patients with ...

Thomas E. Hutson, D.O., Pharm.D., Ph.D., chief of the Hematology Oncology Division in the Department of Internal Medicine at Texas Tech University Health Sciences Center (TTUHSC) and director of the ...

Researchers at Vilnius University have developed an effective approach to liquid biopsy that contributes to the field of ...

Groundbreaking findings from the landmark CLEAR (Clinical trial Comparing Lenvatinib with Ecerolimus or Pembrolizumab in ...

A Waukesha County deputy is battling a "rare, aggressive cancer." Steve Lyles has been with the department for nearly 20 ...

According to Laurence Albiges, MD, PhD, treatment of RCC with cabozantinib, nivolumab, and ipilimumab can cause potentially ...

Dr. Katy Beckermann discusses how a Fotivda and Opdivo combination for renal cell carcinoma compared with Fotivda alone based ...

Exelixis’ next-generation tyrosine kinase inhibitor zanzalintinib is being tested for colorectal cancer, renal cell carcinoma ...

Deputy Steve Lyles has had a rare form of kidney cancer for the past five years. To help Lyles in his fight, the Waukesha ...

The National Cancer Audit Collaborating Centre said prostate, kidney and colon cancers were the worst affected with ...

Patients with localized muscle-invasive bladder cancer (MIBC) who received radiation plus the immune checkpoint inhibitors (ICIs) durvalumab (Imfinzi) and tremelimumab (Imjudo) had durable responses ...

All nine patients treated with a personalized cancer vaccine following removal of their tumors remained cancer-free at a median data cut-off of 34.7 months.